Prompt, effective antimalarial treatment, and supportive care can substantially reduce the rate of mortality from severe malaria. However, many children in malaria-endemic countries do not have access to health facilities or a qualified health care provider and do not receive the necessary care in a... timely fashion. Without rapid detection of danger signs and access to effective treatment, including pre-referral treatment that can be administered in the community level, many of these children with severe malaria die.
In situations where there is no immediate access to a health care facility, WHO recommends the administration of a standard dose of an effective antimalarial medicine as pre-referral treatment before referral to a facility at which complete treatment can be administered.
Rectal artesunate is the WHO-recommended pre-referral intervention in situations where artesunate injection are not feasible for children under the age of 6 years with suspected severe malaria. The intervention reduces the risk of death or permanent disability by up to 50% provided the child is referred to a health facility at which complete treatment can be administered.
This field guide is aimed at supporting the effective deployment of RAS as pre-referral treatment of suspected severe malaria in line with the WHO malaria guidelines.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
This guidance describes a catalogue of indicators for maternal, newborn, child and adolescent health (MNCAH) that can be monitored through health management information system data. It is a module of the WHO Toolkit for Routine Health Information Systems (RHIS) Data and links to relevant indicators ...from other programmatic modules of the WHO toolkit. The document provides guidance on possible analysis and visualization of the indicators, including considerations for interpreting and using the data for decision-making. An annex on data quality considerations for MNCAH managers provides suggestions for reviewing and interpreting routine health facility data through a quality lens.
more
The Roadmap towards ending TB among children and adolescents, third edition builds on the 2013 and 2018 versions. The 2023 version recognizes the progress made over the past five years and outlines priorities and key actions designed to accelerate progress towards the targets elaborated during the 2...023 United Nations General Assembly High-Level Meeting on the fight against TB. Implementation of these key actions at the global, regional, national and sub-national levels is expected to find and treat more children and adolescents with tuberculosis (TB) disease or TB infection, to prevent TB, to improve treatment outcomes and prevent TB-associated disability. The 2023 Roadmap retains the strong focus on TB in children, while also emphasizing the importance of addressing TB among adolescents, and for the first time, among pregnant and post-partum women.
more
Epidemics and pandemics of infectious diseases are occurring more often, and spreading faster and further than ever, in many different regions of the world. The background factors of this threat are biological, environmental and lifestyle changes, among others. A potentially fatal combination of new...ly-discovered diseases, and the re-emergence of many long-established ones, demands urgent responses in all countries. Planning and preparation for epidemic prevention and control are essential. The purpose of the Managing epidemics handbook is to provide expert guidance on those responses. Building on the first edition, the second edition provides concise and basic up-to-date knowledge with which public health officials can respond effectively and rapidly at the very start of an outbreak. Part I of the handbook provides insights on epidemics of the 21st century and offers context on the upsurge of recent epidemics. Part II has been updated and offers 10 key facts about 19 deadly diseases including tips on the interventions required to respond. Part III presents various Tool boxes that summarize guidance on several important topics. The handbook focuses on practical and indispensable things to know about infectious diseases that are most important for national, political and operational decision-makers; it also links readers to more exhaustive WHO guidan
more
Epidemics and pandemics of infectious diseases are occurring more often, and spreading faster and further than ever, in many different regions of the world. The background factors of this threat are biological, environmental and lifestyle changes, among others. A potentially fatal combination of new...ly-discovered diseases, and the re-emergence of many long-established ones, demands urgent responses in all countries. Planning and preparation for epidemic prevention and control are essential. The purpose of the Managing epidemics handbook is to provide expert guidance on those responses. Building on the first edition, the second edition provides concise and basic up-to-date knowledge with which public health officials can respond effectively and rapidly at the very start of an outbreak. Part I of the handbook provides insights on epidemics of the 21st century and offers context on the upsurge of recent epidemics. Part II has been updated and offers 10 key facts about 19 deadly diseases including tips on the interventions required to respond. Part III presents various Tool boxes that summarize guidance on several important topics. The handbook focuses on practical and indispensable things to know about infectious diseases that are most important for national, political and operational decision-makers; it also links readers to more exhaustive WHO guidan
more
Response to the Periodic Epidemic
Daily news report natural catastrophies more and more frequently. The reports include earthquakes, floods, volcanos, famines and droughts. The number of fatalities from natural disasters can vary grately from year to year. Looking at the average over the last ten years, about 45,000 people died each... year worldwide from natural disasters. This issue brief summarizes important facts and guidelines to prepare, prevent and assess future events.
more
Changes in climate, in conjunction with other drivers of mobility, shape human migration. While there is an increasing focus on the adaptive potential of migration, the health impacts of climate-related migration, including planned relocation and forced displacement, have not been thoroughly examine...d. The Intergovernmental Panel on Climate Change stated that migration is currently, and will increasingly be, influenced by environmental degradation and climate change, and that it needs to be addressed in a focused and coordinated manner
more
The mhGAP guideline supports countries to strengthen capacity to deal with the growing burden of mental, neurological and substance use (MNS) conditions and narrow the treatment gap. This new edition includes 30 updated and 18 new recommendations, alongside 90 pre-existing recommendations. This is t...he third iteration of the guideline and reflects 15 years of investment in the mhGAP programme. The revised recommendations ensure that mhGAP continues to offer high-quality, timely, transparent, and evidence-based guidance to support non-specialist health workers in low-income and middle-income countries in providing treatment and care to individuals with MNS conditions.
more
World Health Organization. Country Office for Timor-Leste. (2020). National strategic plan for ending TB 2020--2024. World Health Organization. Country Office for Timor-Leste.
Climate hazards, including extreme heat, are associated with increased risks of developing complications that lead to adverse maternal and perinatal outcomes. These may include multiple causes of maternal and neonatal morbidity and mortality such as gestational diabetes, hyper tensive disorders of p...regnancy, preterm birth, low birth weight and stillbirth. In addition to the health risks related to poor nutrition, water, hygiene and sanitation, the effects of exposure to climate hazards and their aftermath during and after pregnancy can affect mental health and contribute to intergenerational trauma. They may increase stress, anxiety and depression – known risk factors for adverse perinatal outcomes.
more
According to the 2016 Nepal Demographic and Health Survey, 66% of Nepali households use mainly solid fuel for cooking on inefficient stoves. Incomplete fuel combustion of solid fuels emits greenhouse gases and harmful smoke, contributing to climate change, forest degradation, ill health and preventa...ble deaths. Further, the physical burden and time necessary to collect wood for fuel is borne primarily by women and children, thus compromising their productive time, such as social activities and education.
more
Describir barreras y desafíos en la implementación del Programa de Acción Mundial para Reducir las Brechas de Atención en Salud Mental mhGAP, y determinar la asociación entre facilitadores de implementación, accesibilidad, aceptabilidad y supervisión, en Chocó, Colombia. Métodos. Estudio ev...aluativo de corte transversal, con métodos mixtos y secuenciales. Se contó con la participación de 41 personas (30 correspondientes a personal de salud y 11 personas del área administrativa). Se conformaron cinco grupos focales, en el marco de la formación en mhGAP. Se usó la escala de impulsores de implementación, que determinó factores como: facilitadores del sistema para la implementación, acce- sibilidad de la estrategia, adaptación y aceptabilidad, formación y supervisión en la estrategia. También se realizaron entrevistas semiestructuradas, con un posterior análisis temático. Resultados. Se encontró una correlación estadísticamente significativa entre los componentes de la imple- mentación, lo cual fue reafirmado con la información de las entrevistas. A nivel de las barreras señaladas, se destacan factores como dispersión, conflicto armado, la dificultad para cambiar la perspectiva de la zona en la que se vive y los problemas administrativos para acceder a los tratamientos. Estos factores se abordan en una propuesta de ruta de atención. Conclusiones. En mhGAP en el departamento del Chocó, pese a una adecuada aceptabilidad, acceso y supervisión, se evidencian barreras y desafíos de orden social, geográfico, político, cultural y a nivel de la administración en salud, que podrían ser superados con la implementación de rutas intersectoriales de recu- peración, construidas desde el mismo territorio.
more
Este informe presenta los resultados de la colaboración entre la Organización Panamericana de la Salud y sus Estados Miembros para analizar las barreras de acceso a la atención primaria de salud, así como para formular opciones de políticas encaminadas a reducirlas y eliminarlas de manera progr...esiva. El primer capítulo presenta una caracterización de los sistemas de salud de la Región de las Américas y los desafíos para el acceso universal en el contexto de la pandemia de COVID-19. El segundo ofrece un marco metodológico y de análisis para el estudio de las barreras de acceso y la determinación de opciones de políticas. En los capítulos 3 a 6 se presentan estudios de casos centrados en las barreras que enfrentan los grupos en situación de mayor vulnerabilidad en el contexto y la trayectoria de distintas reformas de los sistemas de salud. A modo de conclusión, se presentan recomendaciones generales que permitirán promover la agenda aún inconclusa hacia el acceso universal a la salud y la cobertura universal de salud.
more
La salud mental es de vital importancia para todas las personas, en todas partes. En todo el mundo, las necesidades en materia de salud mental son muchas, pero la respuesta es insuficiente e inadecuada. El Informe mundial sobre la salud mental: Transformar la salud mental para todos ha sido concebid...o para inspirar y fundamentar una mejor salud mental para todas las personas. Al basarse en los datos disponibles más recientes, mostrar ejemplos de buenas prácticas en todo el mundo y transmitir la experiencia de las propias personas, en este informe se pone de relieve por qué es necesario el cambio y dónde, y cuál es la mejor manera de lograrlo. En el informe se insta a todas las partes interesadas a que colaboren para profundizar en el compromiso y el valor que se atribuye a la salud mental, reconfigurar los entornos que influyen en la salud mental y fortalecer los sistemas de atención de la salud mental. La salud mental es mucho más que la ausencia de enfermedad: es una parte intrínseca de nuestra salud y bienestar individual y colectivo. Como se muestra en el presente Informe mundial sobre la salud mental, para alcanzar los objetivos mundiales establecidos en el Plan de acción integral sobre salud mental 2013‑2030 de la OMS y los Objetivos de Desarrollo Sostenible debemos transformar nuestras actitudes, acciones y enfoques para promover y proteger la salud mental, así como para proporcionar cuidados y atención a quienes lo necesitan.
more
The World Health Organization (WHO) Global Tuberculosis Report 2021 estimated that, in 2020, tuberculosis (TB) was the second most common infectious disease killer after coronavirus disease (COVID-19) and the 13th leading cause of death (1). Twenty-five per cent (25%) of the world’s population has... latent TB infection, which can develop into disease. In 2020, WHO estimated that 9.9 million people fell ill with TB, but only about 5.8 million (60%) were diagnosed, reported and treated, an 18% fall from 7.1 million in 2019. WHO also estimates that, between 2019 and 2020, global TB mortality increased from 1.2 to 1.5 million, a 5.6% increase
more
The World Health Organization (WHO) Global Tuberculosis Report 2021 estimated that, in 2020, tuberculosis (TB) was the second most common infectious disease killer after coronavirus disease (COVID-19) and the 13th leading cause of death (1). Twenty-five per cent (25%) of the world’s population has... latent TB infection, which can develop into disease. In 2020, WHO estimated that 9.9 million people fell ill with TB, but only about 5.8 million (60%) were diagnosed, reported and treated, an 18% fall from 7.1 million in 2019. WHO also estimates that, between 2019 and 2020, global TB mortality increased from 1.2 to 1.5 million, a 5.6% increase
more